BioVie Inc has a consensus price target of $10.8 based on the ratings of 5 analysts. The high is $27 issued by B. Riley Securities on November 30, 2021. The low is $3 issued by ThinkEquity on July 1, 2024. The 3 most-recent analyst ratings were released by ThinkEquity, Oppenheimer, and Cantor Fitzgerald on July 1, 2024, November 30, 2023, and August 22, 2023, respectively. With an average price target of $6.33 between ThinkEquity, Oppenheimer, and Cantor Fitzgerald, there's an implied 89.05% upside for BioVie Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for BioVie (NASDAQ:BIVI) was reported by ThinkEquity on July 1, 2024. The analyst firm set a price target for $3.00 expecting BIVI to fall to within 12 months (a possible -10.45% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for BioVie (NASDAQ:BIVI) was provided by ThinkEquity, and BioVie initiated their buy rating.
There is no last upgrade for BioVie
There is no last downgrade for BioVie.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a initiated with a price target of $0.00 to $3.00. The current price BioVie (BIVI) is trading at is $3.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.